Why the study?
Does doxorubicin alter hepatic proteome acetylation status and induce an apoptotic environment in male F344 rats?
Does doxorubicin alter hepatic proteome acetylation status and induce an apoptotic environment in male F344 rats?
Acute doxorubicin treatment in rats decreases hepatic proteome lysine acetylation and activates caspase-12 without inducing a full proapoptotic environment.
Answers are grounded in this paper and cite their sources.
Suggests partial apoptotic signaling from doxorubicin in rat liver; hypothesis-generating for toxicity mechanisms and requires human validation.
AIM: To determine if doxorubicin (Dox) alters hepatic proteome acetylation status and if acetylation status was associated with an apoptotic environment. METHODS: Doxorubicin (20 mg/kg; Sigma, Saint Louis, MO; n = 8) or NaCl (0.9%; n = 7) was administered as an intraperitoneal injection to male F344 rats, 6-wk of age. Once animals were treated with Dox or saline, all animals were fasted until sacrifice 24 h later. RESULTS: Dox treatment decreased proteome lysine acetylation likely due to a decrease in histone acetyltransferase activity. Proteome deacetylation may likely not be associated with a proapoptotic environment. Dox did not increase caspase-9, -8, or -3 activation nor poly (adenosine diphosphate-ribose) polymerase-1 cleavage. Dox did stimulate caspase-12 activation, however, it likely did not play a role in apoptosis induction. CONCLUSION: Early effects of Dox involve hepatic proteome lysine deacetylation and caspase-12 activation under these experimental conditions.
No takes yet. Share an insight, caveat, or question.
Amie J. Dirks‐Naylor (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: